
Episurf Medical Q2 - Changed strategy

Redeye has a neutral stance on Episurf Medical's Q2 report as sales have yet to take off. However, we see that its customer base is expanding nicely, and we argue that the most interesting news relates to its changed strategy. We will return with a case review update in which we dive deeper into the implications on the case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Episurf Medical Q2 - Changed strategy